Can I still have a response to a new BCMA-targeted therapy if a previous BCMA-targeted therapy stopped working? 

This is a common question for multiple myeloma patients due to the abundance of BCMA-directed therapies that currently exist in the myeloma treatment landscape. 

A 2024 Blood Advances research abstract shows that treating patients with BCMA-directed therapies after they have received a BCMA-directed CAR T can result in high response rates; however, the durability of those responses can be shorter than what we are used to seeing, often lasting a few months. 

A publication from the latest ASH Conference (2023) shares that the optimal sequencing of BCMA therapy is yet to be determined, and more research is needed on this subject in order to have a clearer picture of efficacy in sequencing. This abstract also emphasizes the importance of BCMA-expression testing and immune profiling when deciding on the next therapies for myeloma patients.